DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

He, YH; Koch, R; Budamagunta, V; Zhang, PY; Zhang, X; Khan, S; Thummuri, D; Ortiz, YT; Zhang, X; Lv, DW; Wiegand, JS; Li, W; Palmer, AC; Zheng, GR; Weinstock, DM; Zhou, DH

Zhou, DH (corresponding author), Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA.; Weinstock, DM (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Dana 510B, Boston, MA 02115 USA.; Weinstock, DM (corresponding author), Harvard Med Sch, 450 Brookline Ave,Dana 510B, Boston, MA 02115 USA.

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020; 13 (1):

Abstract

Background Patients with advanced T cell lymphomas (TCLs) have limited therapeutic options and poor outcomes in part because their TCLs evade apoptosi......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索